{"filing":{"accession_number":"0001493152-26-025061","cik":"0001716947","ticker":"ENSCW","company_name":"Ensysce Biosciences, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/form8-k.htm"},"events":[{"id":10677,"run_id":9365,"accession_number":"0001493152-26-025061","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Ensysce Biosciences received notice from Nasdaq on May 21, 2026, that it is subject to delisting due to non-compliance with the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan or face delisting, with a potential 180-day extension if the plan is accepted. This is a classic delisting risk disclosure under Item 3.01.","company_name":"Ensysce Biosciences, Inc.","ticker":"ENSCW","filing_date":"2026-05-22","submitted_at":null,"items":null}],"classifications":[{"id":7052,"accession_number":"0001493152-26-025061","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Ensysce Biosciences received notice from Nasdaq on May 21, 2026, that it is subject to delisting due to non-compliance with the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan or face delisting, with a potential 180-day extension if the plan is accepted. This is a classic delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:56:00.273390+00:00","company_name":"Ensysce Biosciences, Inc.","ticker":"ENSCW","filing_date":"2026-05-22"}]}